US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Alvotech - Ordinary Shares (NQ:ALVO)

4.750 +0.130 (+2.81%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
News headline image
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint 
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For November 28, 2023 ↗
Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion. 
Via Benzinga
News headline image
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
From Alvotech
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023 ↗
 
Via Benzinga
News headline image
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
From Alvotech
Via GlobeNewswire
News headline image
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Kashiv Biosciences LLC
Via Business Wire
News headline image
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023 ↗
 
Via Benzinga
News headline image
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Changes to the Leadership Team
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For August 30, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter. 
Via Benzinga
News headline image
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure 
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and FMC and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >